Features of zofenopril and enalapril in patients with stable ischemic heart disease in combination with arterial hypertension

Cover Page

Cite item

Full Text

Abstract

Objective. Optimization of drug therapy in patients with stable coronary heart disease and arterial hypertension (AH) in the application of ACE inhibitors: zofenopril compared with enalapril. Material and methods. We studied 80 patients with stable angina II-III functional class (FC) and AG 1-2 degree (Mean age 58.8±8.8 years) who were randomly divided into 2 groups of observation for 40 people in each: 1 - receiving zofenopril, 2 - enalapril - composed of basic therapy consisting of nitrates, .-blocker, statin, aspirin. The duration of follow-up was 6 months. At baseline and in the dynamics of all patients underwent clinical, laboratory and instrumental studies. It evaluated the quality of life through «Seattle questionnaire» for patients with angina. The daily monitoring of blood pressure at the same time with an electrocardiogram, treadmill test according to the modified protocol R.Bruce, echocardiography was conducted. Conclusion. The use of zofenopril, more than enalapril leads to significantly improved quality of life, exercise tolerance, normalizes the diurnal profile of blood pressure, reduces episodes of ischemia.

About the authors

A. G Evdokimova

A.I.Evdokimov Moscow State University of Medicine and Dentistry of the Ministry of Health of the Russian Federation

Email: Aevdokimova@rambler.ru
д-р мед. наук, проф. каф. госпитальной терапии №2 лечебного фак-та ГБОУ ВПО МГМСУ им. А.И.Евдокимова 127473, Russian Federation, Moscow, ul. Delegatskaia, d. 20, str. 1

A. V Smetanin

A.I.Evdokimov Moscow State University of Medicine and Dentistry of the Ministry of Health of the Russian Federation; City Clinical Hospital №115 of the Department of Health of Moscow

заочный аспирант каф. госпитальной терапии №2 лечебного фак-та ГБОУ ВПО МГМСУ им. А.И.Евдокимова, врач-кардиолог филиала №1 ГП №79 ГБУЗ ГП №115 127473, Russian Federation, Moscow, ul. Delegatskaia, d. 20, str. 1; 123308, Russian Federation, Moscow, ul. Dem'iana Bednogo, d. 8

V. V Evdokimov

A.I.Evdokimov Moscow State University of Medicine and Dentistry of the Ministry of Health of the Russian Federation

канд. мед. наук, доц. каф. госпитальной терапии №2 лечебного фак-та ГБОУ ВПО МГМСУ им. А.И.Евдокимова 127473, Russian Federation, Moscow, ul. Delegatskaia, d. 20, str. 1

E. V Kovalenko

A.I.Evdokimov Moscow State University of Medicine and Dentistry of the Ministry of Health of the Russian Federation

доц. каф. госпитальной терапии №2 лечебного фак-та ГБОУ ВПО МГМСУ им. А.И.Евдокимова 127473, Russian Federation, Moscow, ul. Delegatskaia, d. 20, str. 1

E. V Kiyakbaeva

A.I.Evdokimov Moscow State University of Medicine and Dentistry of the Ministry of Health of the Russian Federation

сотр. каф. госпитальной терапии №2 лечебного фак-та ГБОУ ВПО МГМСУ им. А.И.Евдокимова 127473, Russian Federation, Moscow, ul. Delegatskaia, d. 20, str. 1

References

  1. Диагностика и лечение хронической ишемической болезни сердца. Клинические рекомендации (2013). Кардиологич. вестн. 2015; 3: 3-33.
  2. Марцевич С.Ю. Современные принципы терапии больных ишемической болезнью сердца. РМЖ. 2015; 5: 256-9.
  3. Кукес В.Г., Аникин Г.С. Эффективность зофеноприла при сердечно - сосудистых заболеваниях//Системные гипертензии. 2014; 11 (2): 59-62.
  4. Евдокимова А.Г., Евдокимов В.В., Сметанин А.В., Кожина Н.А. Эффективность применения иАПФ у больных ИБС и АГ, основанная на принципах доказательной медицины (фокус на зофеноприл)//Consilium Medicum. 2014; 16 (10): 61-7.
  5. Карпов Ю.А. Ингибиторы ангиотензинпревращающего фермента как основная терапия у больных с сердечно - сосудистыми заболеваниями//Consilium Medicum. 2010; 12 (10): 62-6.
  6. Napoli C. Safety and efficacy of the sulfhydryl ACE-inhibitor zofenopril in the management of cardiovascular disease. Clin Med Ther 2009; 1: 847-53.
  7. Efficacy of Perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double - blind, placebo - controlled, multicentre trial (the EUROPA study). Lancet 2003; 362: 782-8.
  8. Rodriguez-Granillo G.A. Long - term effect of Perindopril on coronary atherosclerosis progression (from the Perindopril's Prospective Effect on Coronary Atherosclerosis by Angiography and Intravascular Ultrasound Evaluation [PERSPECTIVE] Study). Am J Cardiol 2007; 100: 159-63.
  9. Swedberg K, Held P, Kjekshus J et al. for the CONSENSUS II Study Group. Effects of the early administration of enalapril on mortality in patients with acute myocardial infarction. N Engl J Med 1992; 327: 678-84.
  10. The HOPE Study Investigators. Effects of an angiotensin - converting enzyme inhibitor, ramipril, on death from cardiovascular causes, myocardial infarction, and stroke in high - risk patients. N Engl J Med 2000; 342: 145-53.
  11. The SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med 1992; 327 (10): 685-91.
  12. Барна О.Н. Эволюция ингибиторов АПФ: фокус на зофеноприл. proCARDIO. 2013; 1 (167): 6-11.
  13. Бубнова М.Г. Возможности современного иАПФ зофеноприла в клинической практике: кардиопротективные антиишемические и антиангинальные эффекты. КардиоСоматика. 2013; 4 (1): 62-71.

Copyright (c) 2016 Eco-Vector

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies